PF-06372865（Cat No.:I015548）is a selective, orally bioavailable positive allosteric modulator of GABA-A receptors, developed by Pfizer. Unlike traditional benzodiazepines, it shows preferential activity at α2 and α3 subunit-containing GABA-A receptors, which are linked to anxiolytic and anticonvulsant effects, while sparing α1-mediated sedation and motor impairment. This receptor subtype selectivity makes PF-06372865 a promising candidate for treating epilepsy, anxiety disorders, and related neurological conditions with an improved safety and tolerability profile. Preclinical and early clinical studies highlight its potential to deliver targeted GABAergic modulation for therapeutic use.